Western drug agencies need to step up cooperation to head off a repeat of the recent scandal over tainted heparin and protect patients from counterfeits, the head of EMEA said June 6, according to Reuters.
"Heparin is a classic example of how things can go wrong," Thomas Lonngren told reporters at the organization's London headquarters.
"We have to see how, on an international level, we can cooperate to ensure that those regulatory agencies in Asia and China are up to standard in order to control their market and their manufacturing." Part of the answer may be joint programs of inspections of foreign factories by Western watchdogs.
Lonngren said FDA had agreed to ...